Metformin, cheap and widely used for diabetes, takes a swipe at cancer
© Biodiversity Heritage Library, adapted by M. Atarod
Like an aging actor rediscovered after being typecast for years, the long-standing diabetes drug metformin is poised to reinvent itself. A wealth of studies suggests the drug has cancer-fighting properties, and clinical trials are now under way to prove it.
Metformin’s impact could be huge. “We believe that if this drug works, it will save between 100,000 and 150,000 lives a year worldwide because it is readily administered in countries that don’t have a lot of money for drugs,” says Vuk Stambolic, a molecular biologist at the University of Toronto. Also encouraging is the wide array of cancers metformin may treat — uterine, liver, pancreatic, colon, lung, ovarian and breast. Metformin may even help prevent cancer in people at high risk.
Metformin, also sold as Glucophage, has a long safety record and side effects that are milder than most cancer drugs. It is easy to store and take because it’s a pill, not an injection. As a result,